{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:53:09Z","timestamp":1792756389982,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jhep.2019.11.004","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T12:54:53Z","timestamp":1573736093000},"page":"658-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9338-8854","authenticated-orcid":false,"given":"Gamal","family":"Shiha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabiel N.H.","family":"Mikhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Easterbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.11.004_bib1","series-title":"Global hepatitis report, 2017","author":"WHO","year":"2017"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2019.11.004_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/liv.12063","article-title":"Best strategies for global HCV eradication","volume":"33","author":"Hagan","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.11.004_bib3","series-title":"Egypt Health Issues Survey (EHIS)","author":"El-Zanaty","year":"2015"},{"key":"10.1016\/j.jhep.2019.11.004_bib4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","article-title":"The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt","volume":"355","author":"Frank","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.11.004_bib5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2893.2011.01576.x","article-title":"HCV burden of infection in\u00a0Egypt: results from a nationwide survey","volume":"19","author":"Guerra","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.11.004_bib6","series-title":"Plan of Action for the Prevention, Care & Treatment of Viral Hepatitis. Egypt 2014-2018","year":"2012"},{"key":"10.1016\/j.jhep.2019.11.004_bib7","series-title":"Egypt Demographic and Health Survey","author":"El-Zanaty","year":"2008"},{"key":"10.1016\/j.jhep.2019.11.004_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajg.2014.04.003","article-title":"The current and future disease burden of chronic hepatitis C virus infection in Egypt","volume":"15","author":"Waked","year":"2014","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.11.004_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/HMER.S113681","article-title":"Hepatitis C infection in Egypt: prevalence, impact and management strategies","volume":"9","author":"Gomaa","year":"2017","journal-title":"Hepat Med"},{"key":"10.1016\/j.jhep.2019.11.004_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13186","article-title":"The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment","volume":"37","author":"Kandeel","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.11.004_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhep.2016.10.027","article-title":"The HCV care continuum does not end with cure: a call to arms for the prevention of reinfection","volume":"66","author":"Falade-Nwulia","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib12","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S2468-1253(18)30139-0","article-title":"An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project","volume":"3","author":"Shiha","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2468-1253(18)30336-4","article-title":"Hepatitis C incidence 3 years after implementation of an educate, test, and treat programme in an Egyptian village","volume":"4","author":"Shiha","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib14","first-page":"324","article-title":"Lessons for guidelines from the diffusion of innovations","volume":"21","author":"Rogers","year":"1995","journal-title":"Jt\u00a0Comm J Qual Improv"},{"key":"10.1016\/j.jhep.2019.11.004_bib16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.004_bib17","series-title":"Guidelines for the Screening, Care and Treatment of Persons With Hepatitis C Infection","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.jhep.2019.11.004_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.ELX.0000454686.81811.1a","article-title":"Comparison between transient elastography (Fibroscan) and liver biopsy for the diagnosis of hepatic fibrosis in chronic hepatitis genotype 4","volume":"4","author":"Shiha","year":"2014","journal-title":"Egypt Liver J"},{"key":"10.1016\/j.jhep.2019.11.004_bib19","series-title":"International Ethical Guidelines for Biomedical Research Involving Human Subjects","year":"1993"},{"key":"10.1016\/j.jhep.2019.11.004_bib20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/jgh.13485","article-title":"Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: the case of Greece","volume":"32","author":"Gountas","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6629a2","article-title":"The role of screening and treatment in National Progress toward hepatitis C elimination - Georgia, 2015-2016","volume":"66","author":"Nasrullah","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2019.11.004_bib22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/s12879-017-2767-0","article-title":"Survey of programmatic experiences and challenges in delivery of hepatitis B and\u00a0C testing in low- and middle-income countries","volume":"17","author":"Ishizaki","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2019.11.004_bib23","series-title":"Guidelines for the Prevention, Care and Treatment of Persons With Chronic Hepatitis B Infection","author":"WHO","year":"2015"},{"key":"10.1016\/j.jhep.2019.11.004_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21608\/mjvh.2016.4569","article-title":"Sofosbuvir plus ribavirin for treatment-Naive chronic HCV genotype 4 Patients: real-life experience","volume":"2","author":"Shiha","year":"2016","journal-title":"Med J Viral Hepat"},{"key":"10.1016\/j.jhep.2019.11.004_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","article-title":"Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C\u00a0genotype 4","volume":"63","author":"Doss","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib26","series-title":"Guidelines for the Screening, Care and Treatment of Persons With Chronic Hepatitis C Infection","author":"WHO","year":"2018"},{"key":"10.1016\/j.jhep.2019.11.004_bib27","series-title":"AASLD\/IDSA, HCV guidance: Recommendations for Testing, Managing, and Treating Hepatitis C","year":"2018"},{"key":"10.1016\/j.jhep.2019.11.004_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2019.11.004_bib30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","volume":"64","author":"Abergel","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.004_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12072-018-9861-2","article-title":"Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV\u00a0genotype 4 patients: real-life experience","volume":"12","author":"Shiha","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2019.11.004_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2468-1253(16)30002-4","article-title":"Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial","volume":"1","author":"Waked","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2019.11.004_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/liv.13659","article-title":"The impact of treatment of hepatitis C with DAAs on the occurrence of HCC","volume":"38","author":"Roche","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.11.004_bib34","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/liv.13469","article-title":"Hepatitis B in Egypt: a cross-sectional analysis of prevalence and risk factors for active infection from a nationwide survey","volume":"37","author":"Ismail","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.11.004_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib37","series-title":"Ahram Online. 45 million citizens screened so far as part of '100 Million Healthy Lives\u2019 initiative","year":"2019"},{"key":"10.1016\/j.jhep.2019.11.004_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S2468-1253(19)30046-9","article-title":"Hepatitis C virus infection in children and adolescents","volume":"4","author":"Indolfi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2017.11.037","article-title":"Eliminating hepatitis C within low-income countries - the need to cure genotypes 4, 5, 6","volume":"68","author":"Asselah","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.004_bib40","unstructured":"World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. 2016. http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:37:09Z","timestamp":1759174629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819306725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0168827819306725"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.11.004","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}